TY - JOUR
T1 - Neuroendocrine Tumors of the Lung
AU - Randhawa, Simran
AU - Trikalinos, Nikolaos
AU - Patterson, G. Alexander
N1 - Publisher Copyright:
Copyright © 2021 Elsevier Inc. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Pulmonary neuroendocrine tumors (NETs) are relatively rare; however, their incidence is steadily increasing. They now comprise 1% to 2% of all lung cancers. Lung NETs are classified based on the World Health Organization classification into low-, intermediate-, and high-grade tumors. Most patients present with nonspecific symptoms that can result in delayed diagnosis. Bronchoscopy and biopsy are essential to diagnose and classify pulmonary NETs. Surgery is the mainstay of therapy and R0 resection is key. Lung preservation surgery, whenever possible, is preferred. There is little role of systemic therapy in NETs. Survival after R0 resection is reasonably good especially in low-grade tumors.
AB - Pulmonary neuroendocrine tumors (NETs) are relatively rare; however, their incidence is steadily increasing. They now comprise 1% to 2% of all lung cancers. Lung NETs are classified based on the World Health Organization classification into low-, intermediate-, and high-grade tumors. Most patients present with nonspecific symptoms that can result in delayed diagnosis. Bronchoscopy and biopsy are essential to diagnose and classify pulmonary NETs. Surgery is the mainstay of therapy and R0 resection is key. Lung preservation surgery, whenever possible, is preferred. There is little role of systemic therapy in NETs. Survival after R0 resection is reasonably good especially in low-grade tumors.
KW - Bronchoscopy
KW - Carcinoid
KW - Neuroendocrine tumors
KW - Sleeve lobectomy
UR - http://www.scopus.com/inward/record.url?scp=85120839712&partnerID=8YFLogxK
U2 - 10.1016/j.thorsurg.2021.05.005
DO - 10.1016/j.thorsurg.2021.05.005
M3 - Review article
C2 - 34696859
AN - SCOPUS:85120839712
SN - 1547-4127
VL - 31
SP - 469
EP - 476
JO - Thoracic surgery clinics
JF - Thoracic surgery clinics
IS - 4
ER -